Combined modality management of advanced cervical cancer including novel sensitizers
- PMID: 35256410
- DOI: 10.1136/ijgc-2021-003137
Combined modality management of advanced cervical cancer including novel sensitizers
Abstract
The management of advanced cervical cancer has evolved with time. Combined modality treatments for cervical cancer have been shown to improve clinical outcomes for these patients. The role of surgery is reviewed in this article for specific situations such as the treatment of bulky lymph nodes and even in the metastatic setting. External beam radiotherapy and brachytherapy techniques have improved which has decreased patient toxicity. Systemic therapy such as chemotherapy, immunotherapy, and novel sensitizing agents have been extensively studied and have shown promising results. The combination of these three different modalities of treatment can be tailored to each specific patient to achieve the best outcomes. We review the recent advances and various international guidelines for the management of cervical cancer in this article.
Keywords: cervical cancer; radiotherapy; surgery.
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.Strahlenther Onkol. 2002 Jul;178(7):378-85. doi: 10.1007/s00066-002-0956-1. Strahlenther Onkol. 2002. PMID: 12163992 Clinical Trial.
-
Outcomes and treatments of IB1 cervical cancers with high recurrence risk: A 13 years' experience.Cancer Radiother. 2018 Dec;22(8):790-796. doi: 10.1016/j.canrad.2018.03.006. Epub 2018 Oct 19. Cancer Radiother. 2018. PMID: 30348607
-
Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy.Jpn J Clin Oncol. 2019 Mar 1;49(3):270-275. doi: 10.1093/jjco/hyy187. Jpn J Clin Oncol. 2019. PMID: 30576504
-
Optimal management of locally advanced cervical carcinoma.J Natl Cancer Inst Monogr. 1996;(21):89-92. J Natl Cancer Inst Monogr. 1996. PMID: 9023835 Review.
-
Cervical cancer: combined modality therapy.Cancer J. 2001 Jul-Aug;7 Suppl 1:S47-50. Cancer J. 2001. PMID: 11504285 Review.
Cited by
-
KORTUC, a novel hydrogen peroxide‑based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer.Oncol Lett. 2023 Jul 20;26(3):378. doi: 10.3892/ol.2023.13964. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559582 Free PMC article.